A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
A Multicenter Randomised Study Comparing the Antiviral Efficacy of Pegylated Interferon-alfa-2a Plus Placebo vs. Pegylated Interferon-alfa-2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey, 06620
- Ankara University Medical Facility; Hepatology Department
-
Bursa, Turkey, 16059
- Uni of Uludag Faculty of Medicine; I, Hastaliklari Anabilim Dali
-
Diyarbakir, Turkey, 10000
- Dicle Uni Medical Faculty; Gastroenterology
-
Istanbul, Turkey, 34390
- Istanbul Uni Cerrahpasa Medical Faculty; Gastroenterolgy
-
Izmir, Turkey, 35100
- Ege Uni Medical Faculty Izmir; Gastroenterology
-
Izmir, Turkey, 35340
- Dokuz Eylul University Medical Faculty; Infection
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients, >/=18 years of age
- chronic hepatitis D
- positive for HBsAg >/=6 months, for anti-HDV >/=3 months and for HDV-RNA at screening
- negative pregnancy test; fertile males and women of childbearing age should use two reliable forms of contraception throughout study
Exclusion Criteria:
- antiviral therapy for chronic hepatitis D within the previous 6 months
- previous therapy with pegylated interferon alfa
- treatment with conventional interferon alfa for >12 months
- hepatitis A or C, or HIV infection
- decompensated liver disease (Childs B-C)
- history or evidence of medical condition associated with chronic liver disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
180mcg sc weekly, 96 weeks
orally daily, 96 weeks
|
|
Experimental: 2
|
180mcg sc weekly, 96 weeks
245mg po daily, 96 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
proportion of patients becoming HDV-RNA negative
Time Frame: week 96
|
week 96
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HDV-RNA levels, HBsAg levels, HBV DNA, biochemical disease activity, liver histology
Time Frame: weeks 48, 96 and after 24 weeks of follow-up
|
weeks 48, 96 and after 24 weeks of follow-up
|
|
Safety and tolerability: adverse events, laboratory parameters, vital signs
Time Frame: throughout 96 weeks of treatment
|
throughout 96 weeks of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Hepatitis A
- Hepatitis D
- Hepatitis D, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Peginterferon alfa-2a
Other Study ID Numbers
Other Study ID Numbers
- ML22364
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.